Aclarion, a Broomfield healthcare technology company focused on treating chronic low back pain, announced the enrollment of its first patients at two additional clinical trial sites, Northwestern Medicine and Scripps Health. This development advances the enrollment progress for its pivotal CLARITY trial.
The CLARITY trial is designed to evaluate whether a new technology, Nociscan, can improve surgical outcomes for patients with chronic low back pain. With the latest enrollments, four out of seven selected clinical sites have begun patient screenings. The enrolled sites also include Texas Back Institute, University of Miami Health, Advocate Health, Keck Medicine of USC, and Johns Hopkins University.
The trial aims to enroll up to 300 patients, and initial results are expected in the third quarter of 2026, after the first cohort completes its three-month follow-up visits. An analysis will focus on pain outcomes reported by patients.
Brent Ness, Chief Executive Officer of Aclarion, said, “The CLARITY trial is a foundational value-creation initiative for Aclarion, and we are encouraged by the pace of site activation, early enrollment, and completed surgeries.”
According to estimates, 266 million people globally suffer from chronic low back pain, making it a significant health issue. Aclarion’s technology aims to improve the accuracy of diagnosing disc-related pain, potentially leading to better treatment outcomes.
The primary source was GlobeNewswire.
